Cross-source evidence timeline
Larazotide research timeline
Follow 13 selected, directly cited source records from September 11, 2017 through August 18, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Clinical trials
ClinicalTrials.gov record NCT05747534↗
PeptideScanner retained ClinicalTrials.gov record NCT05747534 at 2026-11-16T01:45:58.486Z. Its registry update date was 2026-08-18, and PeptideScanner's reviewed identity mapping was larazotide.↗
Added to PeptideScanner November 16, 2026Literature metadata
Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.↗
PubMed lists PMID 40737433 in Science translational medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-30 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 30, 2025 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2022
Literature metadata
Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.↗
PubMed lists PMID 35211683 in Critical care explorations as Journal Article, with publication-date metadata of 2022-02-18 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 18, 2022 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2021
Literature metadata
[Larazotide as an option in case of failure of a gluten-free diet].↗
PubMed lists PMID 26983338 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2016-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 2016 · month precisionAdded to PeptideScanner November 16, 2026
Source year
2018
Literature metadata
Commentary: larazotide acetate - an exciting new development for coeliac patients?↗
PubMed lists PMID 23336683 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 2013 · month precisionAdded to PeptideScanner November 16, 2026Literature metadata
Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply.↗
PubMed lists PMID 23336684 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 2013 · month precisionAdded to PeptideScanner November 16, 2026
Source year
2017
Clinical trials
ClinicalTrials.gov record NCT00492960↗
PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00620451↗
PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00889473↗
PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT01396213↗
PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00362856↗
PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00386490↗
PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00386165↗
PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide.↗
Added to PeptideScanner November 16, 2026